Language Disorders: Clinical Trials

26 trials for Language Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed. 26 Phase 2, 6 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 226Completed 26
Phase 16Completed 6
Phase 32Completed 2

Follow Language Disorders: new trials by email Literature Review of Language Disorders trials Research Report on Language Disorders

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Prior Learning on Word Learning
VAULT Phase 4 - Language Development Disorders
Phase 2CompletedUniversity of Arizona222023-06-012025-06-27
Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)
Transcranial Direct Current Stimulation (tDCS), Word-Naming Activity - Primary Progressive Aphasia
Phase 2CompletedNYU Langone Health112022-12-242024-09-19
Dopaminergic Therapy for Frontotemporal Dementia Patients
Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia
Phase 2CompletedI.R.C.C.S. Fondazione Santa Lucia752021-06-032024-10-22
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
Ecopipam, Placebo - Childhood-Onset Fluency Disorder (Stuttering)
Phase 2CompletedEmalex Biosciences Inc.682020-10-222026-09-23
Speech Entrainment for Aphasia Recovery
SET (Speech Entrainment Therapy) 3 weeks, SET (Speech Entrainment Therapy) 4.5 weeks, SET (Speech Entrainment Therapy) 6 weeks - Aphasia, Aphasia Non Fluent
Phase 2CompletedMedical University of South Carolina802020-08-212025-11-14
Treating Primary Progressive Aphasia (PPA) Using High-definition tDCS
high-definition transcranial direct current stimulation, modified constraint-induced language therapy - Primary Progressive Aphasia
Phase 2CompletedUniversity of Pennsylvania762020-08-172026-10-19
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders
Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). - Language Delay, Language; Developmental Disorder, Expressive
Phase 1 / Phase 2CompletedRussian Academy of Medical Sciences142020-02-012022-05-02
Maximizing Outcomes for Preschoolers With Developmental Language Disorders
the Enhanced Milieu Teaching-Sentence Focus - Developmental Language Disorder
Phase 2CompletedNorthwestern University1082019-04-042026-08-19
Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia
Active TMS, Sham TMS, CILT - Aphasia
Phase 2CompletedH. Branch Coslett862019-03-282025-10-14
PCT for Speech, Language, and Cognitive Intervention in Stroke Patients
PCT, Workbooks - Aphasia, Acquired
Phase 2CompletedThe Learning Corp362019-03-182020-07-27
Building Sentences With Preschoolers Who Use AAC
AAC Generative Language Intervention, Standard of Care / Business as Usual - Down Syndrome, Speech and Language Disorder
Phase 2CompletedUniversity of Central Florida702018-05-112024-01-08
Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study
HD-tDCS (Soterix Medical, Active), HD-tDCS (Soterix Medical, Sham) - Chronic Aphasia
Phase 2CompletedSoterix Medical582015-07-012023-12-05
Brief Behavioral Treatment for Anxiety in Young Children
Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia
Phase 1 / Phase 2CompletedUniversity of South Florida582014-01-012016-10-06
Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine
Fluoxetine - Selective Mutism, Social Anxiety
Phase 2CompletedMichigan State University62014-01-012022-05-18
Brain Stimulation and Aphasia Treatment
Activa Dose II Real tDCS, Activa Dose II Sham tDCS - Aphasia
Phase 2CompletedUniversity of South Carolina742012-04-012019-08-20
Building Complex Language
Complex sentence treatment protocol - Language Development Disorders, Learning Disorders
Phase 1 / Phase 2CompletedGovernors State University312011-04-012013-11-25
Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia
Verb Network Strengthening Treatment - Aphasia
Phase 2CompletedUS Department of Veterans Affairs112011-03-012015-06-09
Randomised Controlled Treatment Study of Selective Mutism
Stimulus fading procedures, Guidance on defocused communication - Selective Mutism
Phase 2CompletedRegionsenter for barn og unges psykiske helse242009-06-012014-06-20
My Scrivener® - Measuring Effectiveness and Dose Response in Children
My Scrivener(R) - Asperger's Syndrome, Dyslexia
Phase 1 / Phase 2CompletedObslap Research LLC1762009-04-012010-10-28
Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
MindFrame System - Ischemic Stroke
Phase 2CompletedMindFrame, Inc.402009-03-012012-07-26

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Aphasia (11)  ·  Stroke (6)  ·  Language (4)  ·  Language Development Disorders (4)  ·  Aphasia, Primary Progressive (3)  ·  Attention Deficit Disorder with Hyperactivity (3)  ·  Mutism (3)  ·  Aphasia, Broca (2)  ·  Central Nervous System Diseases (2)  ·  Communication Disorders (2)  ·  Dementia (2)  ·  Dyslexia (2)  ·  Ischemic Stroke (2)  ·  Speech Disorders (2)

Broader conditions

Pathological Conditions, Signs and Symptoms (26)  ·  Signs and Symptoms (26)  ·  Nervous System Diseases (25)  ·  Neurobehavioral Manifestations (25)  ·  Neurologic Manifestations (25)  ·  Communication Disorders (24)  ·  Speech Disorders (16)  ·  Mental Disorders (12)  ·  Neurodevelopmental Disorders (10)  ·  Brain Diseases (9)  ·  Central Nervous System Diseases (8)  ·  Behavior (6)  ·  Cardiovascular Diseases (6)  ·  Cerebrovascular Disorders (6)

Interventions

Commerce (1)  ·  Fluoxetine (1)  ·  Methods (1)  ·  SET protein, human (1)  ·  Standard of Care (1)  ·  Therapeutics (1)  ·  Transcranial Direct Current Stimulation (1)  ·  carbidopa, levodopa drug combination (1)  ·  ecopipam (1)  ·  pagoclone (1)  ·  rotigotine (1)

Sponsors

Climb Up Kids (1)  ·  Emalex Biosciences Inc. (1)  ·  Endo USA Inc., a Keenova Therapeutics Company (1)  ·  Governors State University (1)  ·  H. Branch Coslett (1)  ·  I.R.C.C.S. Fondazione Santa Lucia (1)  ·  Lamar University (1)  ·  Medical University of South Carolina (1)  ·  Michigan State University (1)  ·  MindFrame, Inc. (1)  ·  NYU Langone Health (1)  ·  Northwestern University (1)  ·  Obslap Research LLC (1)  ·  Regionsenter for barn og unges psykiske helse (1)  ·  Russian Academy of Medical Sciences (1)

Countries

United States (21)  ·  Germany (1)  ·  India (1)  ·  Italy (1)  ·  Norway (1)  ·  Russia (1)

Top investigators

Abhishek Datta, Ph.D (1)  ·  Alessandro Martorana, MD, PhD (1)  ·  Alexander A Ostanin, MD, PhD (1)  ·  Ann Kaiser, PhD (1)  ·  Atul R Mahableshwarkar, MD, DFAPA (1)  ·  Bruce Crosson, PhD (1)  ·  Catherine H Balthazar, PhD (1)  ·  Cheryl M Scott, PhD (1)  ·  Devendra Mehta, MBBS MSC MRCP (1)  ·  Elena R Chernykh, MD, PhD (1)  ·  Gayatri Devi, MD (1)  ·  Giacomo Koch, MD (1)  ·  H. Branch Coslett, MD (1)  ·  Hanne Kristensen, MD, PhD (1)  ·  Jed Magen, DO (1)

Results publications

PMID 23106988, PMID 25267381, PMID 29357099, PMID 30128538, PMID 32878377, PMID 33643204, PMID 40809903

NIH funding

R01DC007387 (1), R01DC015642 (1), R01DC016321 (1), R01DC016800 (1), R15DC009027 (1), R44NS092144 (1), U01DC011739 (1), U01DC017521 (1)